Treatment Journey From Diagnosis to the Successful Implementation of a Long-Acting Injectable Antipsychotic Agent in Young Adults With Schizophrenia

Abstract

Objective: Long-acting injectable antipsychotic agents (LAIs) are effective in schizophrenia relapse prevention but are often underutilized. This study aims to understand treatment patterns leading to a successful LAI implementation following schizophrenia diagnosis in a large dataset that included commercially insured patients in the United States. Methods: Patients aged 18-40 years with a first schizophrenia diagnosis (per ICD-9 or ICD-10 criteria), successful second-generation LAI implementation (defined a priori as ≥ 90 consecutive days of use), and ≥ 1 second-generation oral antipsychotic agent (OA) were identified from

Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

“…In addition to oral antipsychotics, long-acting injectable (LAI) formulations of antipsychotics have been developed that relieve patients from the need to receive their medication daily [ 13 – 15 ] and have thus improved treatment adherence and disease management [ 16 ] as well as superior outcomes in comparison to their orally administered counterparts [ 17 , 18 ]. However, unmet clinical need persists with regards to LAIs achieving adequate therapeutic plasma levels at treatment initiation [ 14 , 19 , 20 ], as well as gaps in the evidence of and opportunities for improvements in their long-term safety profiles [ 17 , 21 ].…”